How sFlt-1 can help after preeclampsia diagnosis. (Mini-commentary on BJOG-20-0485.R2)

Daniel L. Rolnik, Aris T. PapageorghiouAuthorea 2020 · DOI

Introduction

Preeclampsia remains a leading cause of maternal and neonatal morbidity and mortality worldwide. While significant progress has been made in the early prediction and prevention of the disease, managing patients once a diagnosis has been established—particularly in early-onset cases—remains a complex clinical challenge. Current strategies focus on first-trimester screening (11–14 weeks) using a combination of maternal characteristics, uterine artery Doppler, and biomarkers like placental growth factor (PlGF). When high-risk patients are identified early and prescribed 150 mg of aspirin, the incidence of preeclampsia before 32 weeks can be reduced by as much as 90%.

However, screening is not universal, and aspirin is not a panacea. For the women who still develop early-onset preeclampsia, clinicians must decide between the risks of prematurity associated with early delivery and the risks of maternal or fetal complications associated with expectant management. This commentary explores recent research by Peguero et al. (BJOG 2020) regarding the use of soluble fms-like tyrosine kinase 1 (sFlt-1) as a longitudinal tool for risk stratification after diagnosis.

From Diagnosis to Prognosis

The sFlt-1:PlGF ratio is already a validated tool for the rule-out of preeclampsia in women with suspected disease. The PROGNOSIS study (Zeisler H et al., 2016) established that a ratio below 38 has a negative predictive value of 99.3% for the need for delivery within the subsequent week. While this is invaluable for reducing unnecessary hospitalizations in suspected cases, its utility after a confirmed diagnosis has been less clear.

Peguero and colleagues shifted the focus from a single "snapshot" measurement to the rate of change in these biomarkers—specifically the "delta sFlt-1." By tracking 63 women with early-onset preeclampsia from diagnosis to delivery, the researchers sought to determine if the trajectory of these biomarkers could predict the interval to delivery and the likelihood of adverse outcomes.

Key Findings: The Power of the "Delta"

The study revealed several critical insights into the biological progression of the disease:

  • sFlt-1 Trajectory as a Predictor: Changes in sFlt-1 levels were significantly more pronounced in women who later developed complications. This "delta sFlt-1" was negatively associated with the interval to delivery, meaning a sharper rise in the protein indicated a more rapid disease progression.
  • Superiority Over Static Scores: The rate of change in sFlt-1 outperformed both single-point admission measurements and previously published clinical risk scores in predicting maternal and fetal complications.
  • The Specificity of sFlt-1: Interestingly, while PlGF is a vital component of early-onset screening, the study found no significant association between the change in PlGF levels and the development of adverse outcomes after diagnosis. The prognostic power appears to be driven primarily by sFlt-1.

Clinical Implications

These findings suggest that serial sFlt-1 measurements could serve as a "biological clock" for clinicians managing early-onset preeclampsia. By identifying women at lower risk of immediate complications, doctors can more confidently pursue expectant management to allow for further fetal development. Conversely, identifying women with a high delta sFlt-1 allows for the timely administration of corticosteroids for fetal lung maturation and the urgent transfer of the mother to tertiary healthcare facilities equipped with advanced neonatal intensive care units.

Limitations and Future Directions

While the results are promising, the Peguero study was limited by a small sample size of 63 women. Larger, multi-center prospective trials are necessary to establish standardized "delta" thresholds for clinical use. Furthermore, there remains a gap between clinical evidence and implementation; while early screening is feasible, real-world physician compliance with aspirin protocols varies significantly (29% in usual care versus 99% in implementation studies).

Conclusion

The shift from using sFlt-1:PlGF as a one-time diagnostic tool to using serial sFlt-1 measurements as a prognostic indicator represents a significant step forward in personalized obstetric care. For cases where prevention fails, longitudinal biomarker monitoring offers a potential roadmap for navigating the delicate balance between maternal safety and neonatal maturity.

Summary updated

Abstract

Measurement of maternal serum soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), and the ratio between the two, has been shown to predict preeclampsia. In women with suspected preeclampsia, an sFlt-1: PlGF ratio below 38 rules out the need for delivery in the subsequent week with a negative predictive value of 99.3% (95% CI 97.9 to 99.9%) (Zeisler H et al. , N Engl J Med 2016;374:13-22). This test may be of particular benefit for women at low risk of developing the disease in the short term, as it may reduce unnecessary follow-up, investigations and admissions (Cerdeira ASet al. , Hypertension 2019;74:983–990).But do these biomarkers have a potential use in women after preeclampsia is diagnosed? This has not been studied extensively. In this issue of BJOG, Peguero and colleagues report the results of a study in which the changes in sFlt-1 and PlGF levels were examined in 63 women with early-onset preeclampsia from diagnosis to delivery (Peguero A et al. , BJOG 2020). Whilst no association between the change in PlGF levels and the development of adverse outcomes was evident, changes in sFlt-1 levels were significantly more pronounced in women who later developed complications and negatively associated with interval to delivery. This change (i.e., the delta sFlt-1) also outperformed a previously published risk score and the use of sFlt-1 at admission only.Because prevention is better than cure, identifying high-risk women early and modifying their risk is desirable. Prediction of preeclampsia can now be achieved at 11 to 14 weeks of gestational age by calculation of individual patient risk. The risk calculation is based on a combined screening test that incorporates maternal characteristics, medical history and biomarkers (mean arterial pressure, uterine artery Doppler and PlGF) alongside first trimester combined screening for fetal aneuploidy. This test is particularly accurate for predicting early-onset preeclampsia, identifying nine out of ten of these severe cases (O’Gorman N et al. , Am J Obstet Gynecol. 2016;214(1):103 e1- e12). More importantly, when this high-risk group is given prophylaxis using aspirin 150 mg from the first trimester to 36 weeks, the rate of preeclampsia before 37 and before 32 weeks is reduced by more than 60% and 90%, respectively (Rolnik DL et al. , N Engl J Med. 2017;377(7):613-22). A recent implementation study demonstrated that early screening is not only feasible in a public health care setting, but is also associated with a significant reduction in the rate of preterm preeclampsia and nearly total physician compliance of aspirin use (29% with usual care versus 99% when combined screening is used) (Guy GP et al. , BJOG 2020).Nevertheless, not all women will undergo such early screening, and not all cases will be avoided by aspirin: some women will still develop preeclampsia, and early-onset disease will remain a significant cause of morbidity and mortality, disproportionally driving the disease burden. Hence, the findings of Peguero and colleagues are important and suggest that serial sFlt-1 measurements following a diagnosis of early-onset preeclampsia can still allow risk stratification – identifying women at lower risk of complications who may be eligible for expectant management, and those at higher risk who require prompt administration of steroids and timely transfer to tertiary health care facilities.No disclosures: Completed disclosure of interest forms are available to view online as supporting information.
BibTeX
@misc{rolnik2020how,
  author = {Daniel L. Rolnik and Aris T. Papageorghiou},
  title = {{How sFlt-1 can help after preeclampsia diagnosis. (Mini-commentary on BJOG-20-0485.R2)}},
  year = {2020},
  doi = {10.22541/au.159526724.43490331},
  howpublished = {Authorea},
}
Figure